Английская Википедия:BTRX-246040
Материал из Онлайн справочника
Шаблон:Short description Шаблон:Drugbox
BTRX-246040, also known as LY-2940094, is a potent and selective nociceptin receptor antagonist which is under development by BlackThorn Therapeutics and Eli Lilly for the treatment of major depressive disorder (MDD).[1][2][3] It has demonstrated proof-of-concept clinical efficacy for depression.[4] As of 2017, it is in phase II clinical trials for the treatment of MDD.[1][2][3] It was also under investigation for the treatment of alcoholism, and similarly reached phase II clinical studies for this indication, but development was discontinued.[1]
See also
References
External links
Шаблон:Opioid receptor modulators
Шаблон:Nervous-system-drug-stub